

Erratum to: “EPICO 3.0. Management of non-neutropenic patients in medical wards” [Rev Iberoam Micol. 33 (4) (2016) 216–223]

Fe de errores de: “EPICO 3.0. Tratamiento del paciente no neutropénico en la planta de medicina interna”
<[Rev Iberoam Micol. 33 (4) (2016) 216–223]>

Ricardo Ferrer^{a,*}, Rafael Zaragoza^b, Alejandro H. Rodríguez^c, Emilio Maseda^d, Pedro Llinares^e, Santiago Grau^f, Francisco Álvarez-Lerma^g, Guillermo Quindós^h, Miguel Salavertⁱ, Rafael Huarte^j, EPICO Project Group

^a Intensive Care Department, Vall d'Hebron University Hospital. Shock, organ dysfunction and Resuscitation Research Group (SODIR), VHIR, Barcelona, Spain

^b Intensive Care Medicine Service, Dr. Peset University Hospital, Valencia, Spain

^c Intensive Care Unit, Joan XXIII University Hospital, Tarragona, Spain

^d Anesthesiology Service, La Paz University Hospital, Madrid, Spain

^e Infectious Diseases Service, A Coruña University Complex Hospital, A Coruña, Spain

^f Pharmacy Service, Hospital del Mar, Barcelona, Spain

^g Intensive Care Medicine Service, Hospital del Mar, Barcelona, Spain

^h Microbiology Service, Faculty of Medicine and Dentistry, Basque Country University, Spain

ⁱ Infectious Diseases Service, Hospital La Fe, Valencia, Spain

^j Pharmacy Service, Miguel Servet University Hospital, Zaragoza, Spain

In the article “EPICO 3.0. Management of non-neutropenic patients in medical wards” (Rev Iberoam Micol. 2016;33(4):216–223), de P. Llinares et al., an error has been detected in the “Conflict of Interests” and “Acknowledgements” sections, being corrected:

Conflict of interests

This consensus has been sponsored by MSD Laboratories, Spain. MSD Spain only provided support to this research. MSD contributed neither to the scientific content nor to the final recommendations.

Acknowledgements

This research has the endorsement of the following Spanish Societies: the Spanish Society of Mycology (AEM), the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Anesthesiology, Reanimation and Pain Therapeutics (SEDAR), the Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC), the Spanish Society of Chemotherapy (SEQ), and the Spanish Society of Hospital Pharmacies (SEFH). We thank Carmen Romero and Ainhoa Torres (Entheos Editorial Group) for their excellent work and dedication to this project.

<http://dx.doi.org/10.1016/j.riam.2017.02.004>

DOI of original article: <http://dx.doi.org/10.1016/j.riam.2016.06.003>.

* Autor para correspondencia.

E-mail address: r.ferrer@vhebron.net (R. Ferrer).